Invest your R&D dollars with evidence of efficacy
A longitudinal database provides pharma companies with many years of real-world data that is representative of every cohort in the US census population. Analyzing such information can show adverse effects and overall efficacy in ways that clinical trials of a few months or even a few years cannot replicate.
With this information, drug manufacturers can determine where to focus future R&D efforts, based on efficacy data from drugs with similar mechanisms of action, those that have shown safety and efficacy among certain demographics, and so on.
With the government, payers, and patients constantly demanding lower drug prices, more rigorous clinical trial protocols and more transparency into manufacturer spending and profits, it’s time to start making your most critical decisions based on real-world evidence.